Dassault expands life-sciences AI with ArisGlobal deal and new AI tools
ArisGlobal acquisition expands life-sciences AI platform Dassault agreed to buy ArisGlobal, a drug-safety and compliance software firm, for about $1.8 billion plus up to $200 million in milestone payments. ArisGlobal serves over 200 customers and half of the top 50 biopharma companies, deepening Dassault's life-sciences reach and adding recurring revenue.
This is the period's biggest strategic move, directly expanding a key growth business and supporting future revenue.
Q2 results solid, full-year targets confirmed Dassault reported Q2 revenue up 4% at constant currencies to €1.56 billion, with subscription revenue up 8% and cloud and 3DEXPERIENCE software each up 14%. Operating margin was 30.0% and earnings per share rose 8%. Management confirmed full-year targets, signaling steady demand.
Solid results and confirmed guidance underpin investor confidence in the company's core business.
New AI products launched across Medidata and 3DEXPERIENCE Medidata launched Medidata Plus, an AI layer for clinical trials, with dozens of customers in talks. Dassault also released Virtual Companions AURA, LEO and MARIE on its 3DEXPERIENCE platform. These AI tools aim to speed workflows and deepen customer lock-in.
Shows Dassault is monetizing AI across its key franchises, a potential driver of future growth.
Semiconductor digital twin partnership with Silvaco Silvaco and Dassault will link Silvaco's process simulation with Dassault's SIMULIA tools to create digital twin workflows for chip manufacturing. The partnership extends SIMULIA into semiconductor fabrication, a large new market, and could open additional revenue streams.
A new partnership that broadens Dassault's simulation reach into semiconductors, supporting long-term growth.